학술논문
Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.
Document Type
Article
Author
Clever, Sabrina; Limpinsel, Leonard; Meyer zu Natrup, Christian; Schünemann, Lisa-Marie; Beythien, Georg; Rosiak, Malgorzata; Hülskötter, Kirsten; Gregor, Katharina Manuela; Tuchel, Tamara; Kalodimou, Georgia; Freudenstein, Astrid; Kumar, Satendra; Baumgärtner, Wolfgang; Sutter, Gerd; Tscherne, Alina; Volz, Asisa
Source
Subject
*IMMUNOGLOBULINS
*LUNGS
*DELAYED onset of disease
*SARS-CoV-2
*VACCINATION
*MICE
*COVID-19 vaccines
*
*
*
*
*
*
Language
ISSN
1999-4915
Abstract
The sudden emergence of SARS-CoV-2 demonstrates the need for new vaccines that rapidly protect in the case of an emergency. In this study, we developed a recombinant MVA vaccine co-expressing SARS-CoV-2 prefusion-stabilized spike protein (ST) and SARS-CoV-2 nucleoprotein (N, MVA-SARS-2-ST/N) as an approach to further improve vaccine-induced immunogenicity and efficacy. Single MVA-SARS-2-ST/N vaccination in K18-hACE2 mice induced robust protection against lethal respiratory SARS-CoV-2 challenge infection 28 days later. The protective outcome of MVA-SARS-2-ST/N vaccination correlated with the activation of SARS-CoV-2-neutralizing antibodies (nABs) and substantial amounts of SARS-CoV-2-specific T cells especially in the lung of MVA-SARS-2-ST/N-vaccinated mice. Emergency vaccination with MVA-SARS-2-ST/N just 2 days before lethal SARS-CoV-2 challenge infection resulted in a delayed onset of clinical disease outcome in these mice and increased titers of nAB or SARS-CoV-2-specific T cells in the spleen and lung. These data highlight the potential of a multivalent COVID-19 vaccine co-expressing S- and N-protein, which further contributes to the development of rapidly protective vaccination strategies against emerging pathogens. [ABSTRACT FROM AUTHOR]